FDA meeting for zervimesine detailed by Cognition Therapeutics (CGTX)

Rhea-AI Filing Summary

Cognition Therapeutics, Inc. filed a current report to note that it has issued a press release about completing a Tye C meeting with the U.S. Food and Drug Administration for its drug candidate zervimesine in dementia with Lewy bodies. The company is furnishing this press release as an exhibit to the report, providing investors with an official update on this regulatory interaction.

false 0001455365 0001455365 2026-01-27 2026-01-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 27, 2026

Cognition Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40886		13-4365359
(State or other jurisdiction of incorporation or organization)		(Primary Standard Industrial Classification Code Number)		(I.R.S. Employer Identification No.)

2500 Westchester Ave. Purchase, NY		10577
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (412) 481-2210

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Exchange on Which Registered
Common Stock, par value $0.001 per share		CGTX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Events.

On January 27, 2026, Cognition Therapeutics, Inc. (the “Company”) issued a press release announcing the completion of its Tye C meeting with the U.S. Food and Drug Administration for zervimesine in dementia with Lewy bodies. A copy of the press release is being filed as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are being furnished herewith:

Exhibit No.		Document
99.1		Press Release, dated January 27, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	COGNITION THERAPEUTICS, INC.
Date: January 27, 2026
	By:	/s/ Lisa Ricciardi
	Name:	Lisa Ricciardi
	Title:	President and Chief Executive Officer

FAQ

What did Cognition Therapeutics, Inc. (CGTX) announce in this 8-K?

Cognition Therapeutics, Inc. reported that it issued a press release announcing the completion of its Tye C meeting with the U.S. Food and Drug Administration for zervimesine in dementia with Lewy bodies.

Which drug candidate is mentioned in Cognition Therapeutics, Inc. (CGTX)'s 8-K filing?

The filing refers to zervimesine, which is being studied for dementia with Lewy bodies.

What regulatory agency did Cognition Therapeutics, Inc. (CGTX) meet with?

The company completed a Tye C meeting with the U.S. Food and Drug Administration.

What exhibit did Cognition Therapeutics, Inc. (CGTX) attach to this 8-K?

The company attached Exhibit 99.1, which is a press release dated January 27, 2026, and Exhibit 104, the Cover Page Interactive Data File.

What is the subject of the press release furnished by Cognition Therapeutics, Inc. (CGTX)?

The press release discusses the completion of a Tye C meeting with the U.S. Food and Drug Administration for zervimesine in dementia with Lewy bodies.

Who signed the Cognition Therapeutics, Inc. (CGTX) 8-K report?

The report was signed by Lisa Ricciardi, President and Chief Executive Officer of Cognition Therapeutics, Inc.